Roche reports positive top line Phase II data for CT-388 in obesity
Participants receiving up to 24mg of CT-388 had a placebo-adjusted weight loss of 22.5% at 48 weeks.
Participants receiving up to 24mg of CT-388 had a placebo-adjusted weight loss of 22.5% at 48 weeks.